Cardiol Therapeutics 미래 성장

Future 기준 확인 0/6

Cardiol Therapeutics은 연간 수입과 매출이 각각 22.5%와 76.5% 증가할 것으로 예상되고 EPS는 연간 22.1%만큼 증가할 것으로 예상됩니다.

주요 정보

22.5%

수익 성장률

22.1%

EPS 성장률

Pharmaceuticals 수익 성장	53.6%
매출 성장률	76.5%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	22 Nov 2024

최근 미래 성장 업데이트

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03

수익 및 매출 성장 예측

TSX:CRDL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CAD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-42	-33	-33	3
12/31/2025	N/A	-41	-35	-34	5
12/31/2024	N/A	-38	-25	-25	5
9/30/2024	N/A	-36	-26	-26	N/A
6/30/2024	N/A	-29	-22	-22	N/A
3/31/2024	N/A	-30	-22	-22	N/A
12/31/2023	N/A	-28	-25	-25	N/A
9/30/2023	N/A	-28	-31	-31	N/A
6/30/2023	N/A	-30	-30	-30	N/A
3/31/2023	N/A	-29	-27	-27	N/A
12/31/2022	N/A	-31	-27	-27	N/A
9/30/2022	N/A	-30	-19	-19	N/A
6/30/2022	N/A	-32	-23	-23	N/A
3/31/2022	0	-32	-27	-27	N/A
12/31/2021	0	-32	-24	-24	N/A
9/30/2021	0	-35	-22	-22	N/A
6/30/2021	0	-30	-19	-19	N/A
3/31/2021	N/A	-27	-14	-14	N/A
12/31/2020	N/A	-21	-9	-9	N/A
9/30/2020	N/A	-14	-10	-10	N/A
6/30/2020	N/A	-13	-9	-9	N/A
3/31/2020	N/A	-13	-10	-10	N/A
12/31/2019	N/A	-14	-12	-11	N/A
9/30/2019	N/A	-20	-17	-17	N/A
6/30/2019	N/A	-21	-16	-16	N/A
3/31/2019	N/A	-19	-15	-15	N/A
12/31/2018	N/A	-16	-11	-11	N/A
9/30/2018	N/A	-8	-3	-3	N/A
6/30/2018	N/A	-3	N/A	-2	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CRDL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CRDL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CRDL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CRDL 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: CRDL 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CRDL 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Cardiol Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates upgraded to CA$0.37 loss

No longer forecast to breakeven

Price target increased to CA$4.50

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Recent updates

New major risk - Revenue and earnings growth

Cardiol Therapeutics Inc. to Advance CardiolRx into A Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $13.5 million.

Cardiol Therapeutics Inc. has filed a Follow-on Equity Offering.

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024

President recently bought CA$138k worth of stock

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

New major risk - Share price stability

New minor risk - Share price stability

Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot

New minor risk - Shareholder dilution

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to CA$0.37 loss

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis

No longer forecast to breakeven

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Price target increased to CA$4.50

Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis

Consensus forecasts updated

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces Board Appointments

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis

Price target decreased to CA$7.50

High number of new and inexperienced directors

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Independent Chairman recently bought CA$121k worth of stock

Price target decreased to CA$10.83

Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial

High number of new and inexperienced directors

No longer forecast to breakeven

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Independent Director exercised options to buy CA$97k worth of stock.

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

High number of new directors

Price target increased to CA$9.57

Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million.

Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Consensus forecasts updated

Independent Director exercised options to buy CA$88k worth of stock.

Independent Director recently bought CA$99k worth of stock

New 90-day high: CA$3.72

Cardiol Therapeutics Inc Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase Ii/Iii Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

New 90-day low: CA$2.38

Price target raised to CA$5.28

New 90-day high: CA$3.44